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Background: Current therapy for muscle contusions is usually limited to nonsteroidal anti-inflammatory drugs and/or use of the
RICE principle (rest, ice, compression, elevation); thus, other forms of treatment that can potentially accelerate the rate of healing
are desirable.
Hypotheses: A local injection of platelet-rich plasma (PRP) would lead to accelerated healing rates compared with controls; also,
delayed administration of PRP would lead to a blunted response compared with immediate treatment.
Study Design: Controlled laboratory study.
Methods: Forty-six male Lewis rats each underwent a single blunt, nonpenetrating impact to the gastrocnemius muscle via
a drop-mass technique and subsequently received either a single injection of saline into the area of injury immediately after injury
(controls, n = 11) or rat PRP (either immediately after injury [PRP day 0, n = 12], the first day after injury [PRP day 1, n = 12], or the
third day after injury [PRP day 3, n = 11]). The primary outcome was maximal isometric torque strength of the injured muscle,
which was assessed before injury as well as on postinjury days 1, 4, 7, 10, and 14. All animals were sacrificed on postinjury
day 15. Histological and immunohistochemical analyses were performed on 6 specimens from each group after sacrifice.
Results: The mean platelet concentration in the PRP was 2.19 3 106 (62.69 3 105)/mL. The mean white blood cell count in the
PRP was 22.54 3 103/mL. Each group demonstrated statistically significant decreases in maximal isometric torque strength after
injury when compared with preinjury levels, followed by significant increases back toward baseline values by postinjury day 14
(controls, 90.6% 6 7.90%; PRP day 0, 105.0% 6 7.60%; PRP day 1, 92.4% 6 7.60%; PRP day 3, 77.8% 6 7.90%) (P =
.121). There were no statistically significant differences between the treatment and control groups at any of the time points. There
were also no statistically significant differences between any of the groups in the percentage of centronucleated fibers (controls,
3.31% 6 5.10%; PRP day 0, 0.62% 6 1.59%; PRP day 1, 3.24% 6 5.77%; PRP day 3, 2.13% 6 3.26%) (P = .211) or the presence
of inflammatory cells and macrophages.
Conclusion: In this rat contusion model, a local injection of PRP into the injured gastrocnemius muscle resulted in no significant
differences in functional or histological outcomes, indicating no likely benefit to healing. Additionally, there was no significant difference between immediate or delayed administration of PRP.
Clinical Relevance: Before PRP can be recommended for the treatment of muscle contusion injuries, further translational and
clinical investigations need to be performed.
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debated.5 Therefore, for severe contusions, more effective
treatments are needed.
Platelet-rich plasma (PRP) is a locally administered
agent that is being investigated for use in soft tissue healing. It is a concentrated solution of platelets derived from
whole blood. Although the specific elements of PRP have
yet to be completely defined, a concentration of approximately 1 million platelets/mL has been shown to be clinically useful.16 Activation of the platelets, whether ex
vivo (by thrombin and calcium) or in vivo by exposure to
collagen,7 leads to the local release of growth factors from
the alpha and dense granules located in the platelet.
There are very few data on the effect of PRP on muscle
injuries. A recent study utilizing a rat model found that
PRP treatment resulted in a faster recovery time after

Muscle contusions caused by blunt, nonperforating trauma
and muscle strains are among the most common injuries in
athletes.10 Pain and restricted range of motion due to these
injuries can lead to decreased performance and limited
ability to play. Nonoperative management, including rest,
ice, compression, elevation (RICE), is often considered
the treatment of choice.12 Early mobilization versus immobilization is somewhat controversial, and the benefit
of other adjuvant therapies such as nonsteroidal antiinflammatory drugs and corticosteroid injections is still
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repeated small muscle strain injuries (but not a single
large strain injury).9 However, currently, there are few
published clinical or animal studies investigating the
effects of PRP on healing of skeletal muscle contusions.
In this study, we sought to employ a rat model of muscle
contusion injuries to evaluate the effects of local PRP
administration on muscle healing. We hypothesized that
a local injection of PRP would lead to accelerated healing
rates compared with controls. We also hypothesized that
delayed administration of PRP would lead to a blunted
response compared with immediate treatment.
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of 1 second throughout impaction to provide the most
reliable/reproducible injury.3 A mass weighing 500 g was
dropped from a height of 33 cm onto an impactor shaped
as a sphere on its bottom that directly contacted the skin
over the rat gastrocnemius muscle, causing the injury (Figure 2). A pilot study demonstrated that this protocol results
in a clinically relevant, reproducible injury (see the Appendix, available in the online version of this article at
http://ajsm.sagepub.com/supplemental).

PRP Production
MATERIALS AND METHODS
This study was approved by the Institutional Animal Care
and Use Committee. A total of 46 male Lewis rats aged
approximately 12 weeks each underwent a single blunt,
nonpenetrating impact to the gastrocnemius muscle via
a drop-mass technique. The rats were separated into 4
groups, with each rat receiving an injection into the
injured gastrocnemius muscle in the following manner:
 Rats in group 1 (n = 11) received a single injection of
100 mL of saline within 2 hours of injury (controls).
 Rats in group 2 (n = 12) received a single injection of
100 mL of rat PRP within 2 hours of injury (PRP day 0).
 Rats in group 3 (n = 12) received a single injection of
100 mL of rat PRP on postinjury day 1 (PRP day 1).
 Rats in group 4 (n = 11) received a single injection of
100 mL of rat PRP on postinjury day 3 (PRP day 3).
The mean 6 SD weight of the rats was 319 6 15 g, with
no significant difference between the groups (P = .249).
After the injury, rats were allowed unlimited activity.
The primary outcome measurement was maximal isometric torque strength of the injured muscle, which was performed before injury as well as on postinjury days 1, 4, 7,
10, and 14. All animals were sacrificed on postinjury day
15 (Figure 1).

Muscle Contusion Injury Model
The technique was adapted from that described by Crisco
et al.4 Briefly, the rats were anesthetized and placed in
the prone position with the right hindlimb secured to a platform. The ankle was placed in the neutral position with the
knee extended. Electrodes were placed subcutaneously on
either side of the gastrocnemius muscle of the experimental
leg. The muscle was then stimulated to tetanus for a period

Seventeen male Lewis rats were used for the purpose of
PRP production. We used Lewis rats because they are
syngeneic (ie, inbred and genetically identical), and therefore, the PRP produced precluded any cross-reactivity or
adverse immune reaction. Our laboratory developed a custom protocol for preparing rat PRP (because there were no
commercial systems specific for animals) as follows.
Whole blood was drawn from Lewis rats via an intracardiac puncture after euthanasia by CO2 inhalation. The
blood was pooled and collected in blood tubes containing
the anticoagulant citrate phosphate dextrose. The whole
blood was then centrifuged at 1000g for 15 minutes at
4°C, followed by a 5-minute rest period, followed by
another cycle of centrifugation at 1000g for 15 minutes
at 4°C. (This setting was determined to reliably produce
rat PRP platelet concentrations of at least 4 times the
whole blood levels, after a pilot experiment evaluating different centrifugation times and speeds [results unpublished]). The platelet-rich fraction of the supernatant
was then isolated using a pipette technique and kept at
room temperature.
All injections were performed within 2 hours of PRP
preparation. In brief, 100 mL of the PRP solution was
drawn into a 1-mL tuberculin syringe with a 27-gauge needle. The volume of injection was the same as that previously used in another study utilizing a rat muscle injury
model.9 The injection site was prepped in a sterile fashion,
and the needle was inserted through the skin into the
medial head of the gastrocnemius in the region of injury.
Approximately half of the volume was injected into the
medial gastrocnemius. Then, without completely withdrawing the needle out of the skin, it was redirected into
the lateral head to allow for injection of the remaining volume. No additive was used to activate the PRP before injection as previous work has shown that PRP can be activated
by exposure to collagen alone.7
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Figure 1. Flowchart demonstrating the study design.

Platelet Concentration and Growth Factor Analysis

Histological Analysis

The concentration of platelets in the PRP was determined
using an automated cell counter. Aliquots from each preparation were analyzed for platelet cell count to ensure that
the concentration was at least 4 times the whole blood levels. The concentrations of platelet-derived growth factor
(PDGF), vascular endothelial growth factor (VEGF), and
transforming growth factor–b (TGF-b) were determined
by enzyme-linked immunosorbent assays (Quantikine
Immunoassay Kits; R&D Systems) performed by Harvest
Technologies on an aliquot of prepared PRP.

Upon sacrifice, 6 rats from each group were chosen at random for tissue harvest and histological processing. Briefly,
the injured gastrocnemius muscle was carefully dissected
and placed in formalin for 72 hours. The tissue was then
embedded in paraffin and sectioned in the axial plane in
5 mm–thick slices.

Biomechanical Testing
(Maximal Isometric Torque Testing)
The primary outcome tested was maximal isometric torque strength of the gastrocnemius complex as a percentage of baseline (preinjury) values. For torque testing,
the animal was first sedated with inhalation anesthesia
and placed supine onto a custom platform. The foot was
secured onto a footplate, and the tibia was stabilized
with a Kirschner wire placed through the proximal metaphysis (Figure 3). A C-clamp was used to secure the thigh
to a post with the knee at 90° of flexion. Muscle stimulation was performed using monopolar needle electrodes
placed subcutaneously in the popliteal fossa/proximal
calf. Contraction was induced by stimulation with a
15-mA constant current, and voltage was optimized for
maximum contraction. All isometric contractions were
performed with the foot orthogonal to the tibia (considered 0°). Maximal isometric torque testing was performed
on the injured limb before injury (baseline value), 5
minutes after injury, and then 1, 4, 7, 10, and 14 days
after injury.

Evaluation of Muscle Regeneration
Tissue specimens were stained with hematoxylin and eosin
to evaluate the general morphology and to determine the
number of centronucleated muscle fibers. Centronucleated
fibers are a marker of muscle regeneration.15 Analysis of
regenerating myofibers was performed by counting the
number of fibers in 10 randomly selected microscope fields
per sample. Samples were viewed under 1003 magnification using a light microscope (Nikon Optiphot; Nikon
Corp), and pictures were obtained with a digital camera
(Nikon DMX1200; Nikon Corp) for recording purposes
and later review.

Evaluation of Fibrosis
Masson trichrome staining (IMEB Inc) was used to evaluate the extent of fibrosis in the area of injury. After Masson
trichrome staining, specimens were viewed at 403 magnification using a light microscope, and photomicrographs
were obtained with a digital camera. Areas of fibrosis
were carefully outlined and circumscribed using ImageJ
software (National Institutes of Health). The ratio of the
fibrotic area to the total cross-sectional area (also outlined
using ImageJ software) was calculated to estimate the
degree of fibrosis formation.
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Figure 2. Injury model setup with the rat lying prone and
impactor striking the gastrocnemius of the hindlimb.
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Figure 3. A rat being prepared for torque testing. The foot is
placed on a foot holder attached to a torque sensor, and the
tibia is secured with wire. Stimulation is performed with subcutaneous electrodes (not shown).

Immunohistochemical Analysis
Serial sections were treated with 3% H2O2 to quench
endogenous peroxidase activity, and nonspecific antibody
binding was blocked with serum-free protein block. Each
primary antibody was applied to separate serial sections
for 60 minutes at room temperature. Bound antibodies
were visualized using a biotinylated link antibody and
streptavidin–horseradish peroxidase system developed
with 3,3#-diaminobenzidine (DAB, Dako Corp) as a substrate chromogen. We used the following antibodies to
localize hematopoietic lineage cells: mouse anti-rat ED1
macrophage (ED1 antigen is a lysosomal glycoprotein
expressed only by a subpopulation of macrophages and
monocytes) and mouse anti-rat ED2 macrophage (ED2
antigen is a membrane glycoprotein found only on mature
tissue macrophages) (Serotec Inc). The sections were counterstained with Mayer hematoxylin. Semiquantitative
analysis was performed by reviewing 10 randomly selected
fields per sample at 1003 magnification using a light

microscope and obtaining pictures with a digital camera.
A grading system was used as follows: grade 0 (no positively staining cells), grade 1 (scant number of positively
staining cells in the entire field), grade 2 (moderate number of positively staining cells in the entire field [ie, less
than the majority of cells]), and grade 3 (large number of
positively staining cells in the entire field [ie, the majority
of cells]).

Statistical Analysis
A power analysis using pilot data was performed with the
assistance of the institutional biostatistics department
before commencing the study. The primary outcome measure used for the power analysis was isometric torque
strength. This analysis determined that with a set at .05,
b set at .20, and an effect size of 25%, 12 animals per group
would be required.
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Histological and immunohistochemical data were analyzed with a single-factor analysis of variance (ANOVA)
using SigmaStat software (Systat Software Inc). Data
from contractile testing were analyzed using a 2-way
ANOVA with PRP injection date and days after injury and
a cross-effect between the two as parameters. The variation
between individual rats within each injection group was
treated as a random effect. Tukey honest significant difference (HSD) post hoc tests were used to identify intraeffect
significant differences. The 2-way ANOVA and post hoc
tests were performed using JMP software (SAS Institute
Inc), and statistical differences were considered at a = .05.
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TABLE 1
Platelet and Growth Factor Concentrations
in a Randomly Selected Aliquot of Whole Blood
Used to Prepare PRPa
Platelet
PDGF-AB, VEGF, TGF-b,
Count, 3103/mL
pg/mL
pg/mL ng/mL
PRP
Whole blood
Factor difference

1994
464
4.3

330
125
2.6

18
10
1.8

85
32
2.7

a
PDGF-AB, platelet-derived growth factor–AB; PRP, plateletrich plasma; TGF-b, transforming growth factor–b; VEGF, vascular endothelial growth factor.

RESULTS
Twelve rats underwent the procedure in the immediate
treatment and PRP day 1 groups. Eleven rats underwent
the procedure in the control and PRP day 3 groups because
of anesthetic complications, resulting in 2 accidental death
at the time of surgery.

Platelet and Growth Factor Concentrations
6

The mean platelet concentration in the PRP was 2.19 3 10
(62.69 3 105)/mL. This was over 4 times greater than the
mean whole blood platelet levels in a randomly selected
sample of whole blood obtained before centrifugation. The
mean white blood cell count in the PRP was 22.54 3
103/mL. The mean white blood cell count in rat whole blood
was 5.21 3 103/mL.
In the aliquot of PRP tested for specific growth factors,
the PDGF-AB, VEGF, and TGF-b concentrations were
330 pg/mL, 18 pg/mL, and 85 ng/mL, respectively. The
PDGF-AB, VEGF, and TGF-b concentrations were
125 pg/mL, 10 pg/mL, and 32 ng/mL, respectively, in whole
blood. Thus, PDGF-AB levels were 2.6 times greater in the
PRP compared with whole blood levels from the same sample; VEGF levels were 1.8 times greater, and TGF-b levels
were 2.7 times greater, respectively. (In that specific aliquot, the platelet concentration in the PRP was 1994 3
103/mL, whereas in whole blood, it was 464 3 103/mL, which
is nearly 4.3 times less than that in PRP) (Table 1).

Isometric Torque Testing
Each group demonstrated statistically significant
decreases (P \ .05) in maximal isometric torque strength
after injury compared with preinjury levels, with the lowest values observed by approximately day 4 to 7 (Figure
4). This was followed by significant increases (P \ .05)
back toward baseline values by postinjury day 14. There
were no statistically significant differences between the
control and treatment groups at any of the time points
(P = .1208). The only statistically significant differences
were between testing days themselves (P \ .0001). A
Tukey HSD post hoc test showed that day 0 testing was
significantly different from days 1, 4, 7, and 10 (but not
day 14) (P \ .0001). Day 14 was significantly different
from days 4 and 7 (P \ .001), day 10 (P = .0007), and day

1 (P = .0334). Day 7 was significantly different from days
1 and 10 (P \ .0001), and day 4 was significantly different
from day 10 (P = .0003) (Figure 4).

Histological Analysis
Histological analysis was performed on samples retrieved
after sacrifice (postinjury day 15). The control group demonstrated the highest mean percentage of centronucleated
fibers per visual field (3.31% 6 5.10%), and the PRP day
0 group demonstrated the lowest (0.62% 6 1.59%). The
PRP day 1 group had a mean percentage of 3.24% 6
5.77%, and the PRP day 3 group had a mean percentage
of 2.13% 6 3.26%. However, the difference in the percentage of centronucleated muscle fibers between treatment
and control groups was not statistically significant
(P = .211) (Figure 5).
The PRP day 1 group demonstrated the highest percentage of volume of fibrotic (scar) tissue (3.11% 6 3.65%), and
the control group demonstrated the lowest (0.89% 6
1.95%). The PRP day 0 and PRP day 3 groups had
a mean percentage of volume of 1.37% 6 2.44% and
2.78% 6 4.75%, respectively. However, the difference in
the percentage of fibrotic (scar) tissue was not statistically
different between any of the groups (P = .158) (Figure 6).

Immunohistochemical Analysis
The group treated with PRP immediately after injury demonstrated the lowest mean immunohistochemical grade
(0.22 6 0.41), whereas the group that received PRP on
postinjury day 3 had the highest mean immunohistochemical grade (0.42 6 0.61). The group treated with PRP on
day 1 and the control group had a mean grade of 0.26 6
0.74 and 0.34 6 0.58, respectively. There were no statistically significant differences in the mean immunohistochemical grade between any of the groups (P = .1158)
(Figure 7).

DISCUSSION
Platelet-rich plasma has received a tremendous amount of
attention both in the medical literature as well as the lay
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press over the last several years. Initial reports demonstrated positive findings, but these studies were limited
primarily to small retrospective case series.18,19,25 In
a case-control study, Sanchez et al25 reported that 6 athletes who underwent open Achilles tendon repair along
with an injection of PRP recovered range of motion sooner
and were able to return to running and training more
quickly than 6 athletes who underwent open Achilles
repair without a PRP injection. Mishra and Pavelko19
reported significant pain relief in patients who received
a single PRP injection for chronic elbow epicondylar pain
at final follow-up.
More recently, clinical studies of higher level quality6,8,21,24 have been published, but these have shown variable results. A recent randomized controlled trial
demonstrated no effect on Achilles tendinitis treated with
a PRP injection and eccentric exercise compared with controls6; however, a randomized controlled trial showed that
PRP treatment of lateral epicondylitis had superior outcomes (pain scores and function) compared with steroid
injections.21 Some criticisms associated with these studies
include the lack of isolated treatment and the use of a treatment (ie, steroid injection) that is not universally regarded
as the gold standard. In addition, other studies, including
a randomized controlled one from our institution, have

shown no benefit in the treatment of rotator cuff injuries
with platelet-rich therapies.2,24,27
Platelet-rich plasma has also been used empirically for
the treatment of muscle injuries, although the literature
on the effects of PRP on muscle healing is scant. Sanchez
et al25 presented a small retrospective series in which
they reported positive findings, but they were limited in
terms of the outcomes tested and the rigor of the study
design. The authors reported performing ultrasoundguided injections of PRP into 22 injured muscles in 20 professional athletes. They noted full functional recovery in all
patients in half the expected recovery time, without evidence of fibrosis and no reinjuries upon the resumption
of normal activities. This study, however, is limited to an
abstract that was presented at the 2nd World Congress
on Regenerative Medicine in 2005 (Sanchez M, Anitua E,
Andia I. ‘‘Application of Autologous Growth Factors on
Skeletal Muscle Healing.’’) with no further follow-up. No
other evidence level 4 or higher clinical study exists
regarding PRP and muscle healing.
In the animal literature, Hammond et al9 used a rat tibialis anterior strain model and found that PRP provided a positive benefit in terms of faster recovery for those rats that had
multiple strain injuries but not in those in the single-strain
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protocol group. The authors speculated that because recovery
from the high-repetition protocol primarily relies on myogenesis, rather than sarcolemmal repair,15 PRP may be more
effective for injuries that rely on muscle regeneration rather
than repair. Recent work by Terada et al26 in mice also
reported positive findings in those treated with a PRP injection and administration of losartan after a muscle contusion
injury. More specifically, the authors reported improvement
in muscle strength after PRP and losartan treatment as
well as enhanced muscle regeneration and angiogenesis
with decreased muscle fibrosis.26
Our study using a muscle contusion model showed no
differences in terms of muscle contractile testing and histological outcomes as well as no evidence of increased inflammation by the time of sacrifice. The fact that our study
showed no positive effect on healing after treatment with
PRP may be because of a number of reasons. We utilized
a rat model of muscle injuries limited to a single contusion
event; as suggested by Hammond et al,9 PRP may be of
greater utility in multiple injury scenarios because these
injuries may rely primarily on a muscle regeneration
mechanism rather than sarcolemmal/muscle repair.
Although it was originally thought that recovery of function after a skeletal muscle injury is predominately associated with the activation and proliferation of myogenic cells
(ie, satellite cells),1,14,23 recent work by Lovering et al15 has
shown that single-repetition muscle strain injuries result
predominately in sarcolemmal (membrane) injuries, followed by early sarcolemmal repair (membrane resealing),
rather than satellite cell activation and proliferation.
Thus, the fact that we found no difference between the
experimental and control groups may be because our
injury model involved a single, large contusion event
rather than multiple injuries.
Additionally, our PRP was prepared according to a protocol that we developed, and we did not rely on a commercial
system. At the time this study was being conducted, there
were no commercially available systems specifically for animal use. Indeed, several other groups had used noncommercial systems for producing rat PRP before this
study.11,13,20,22 These authors reported platelet concentrations in PRP of approximately 3 to 10 times that of whole
blood. We settled on a protocol that resulted in platelet
counts approximately 4 times greater than that in rat whole
blood, as per the recommendation of Marx16 with regard to
human PRP. This resulted in specific growth factor concentrations that were similarly increased several-fold beyond
whole blood values. Because the literature on PRP is still
somewhat limited, there is yet no optimal PRP concentration, volume, or injection schedule that can be relied upon
for ideal results. The PRP that we produced was collected
from rats that were syngeneic (ie, inbred) so that should
have precluded any risk of cross-reaction or enhanced
immune reactivity (although other authors have used rat
species that were not syngeneic without apparent adverse
effects9). In addition, we also chose to utilize the PRP immediately after preparation rather than storing it for later use
to minimize any effects of prolonged storage or freeze/thaw
cycles as well as the fact that this is how it is typically prepared and applied clinically.
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Our study has the following limitations. (1) The study
may have been underpowered to detect small differences
between groups; as mentioned in the Results section,
2 groups had animal numbers that were 1 less than the
intended number. This was because of anesthetic complications that occurred at the time of surgery. Nevertheless,
based on the post hoc statistical analyses, we do not believe
that the addition of 1 animal in each of those 2 groups
would have made a large difference in the outcomes.
(2) The optimal concentration of platelets, timing of injection, and volume of solution to be injected have yet to be
determined, especially in animal models. Additional
research is needed to better define the effects of these variables. (3) The PRP that we generated had a relatively high
concentration of white blood cells. Although the exact role
of leukocytes in PRP is unclear, there is some evidence that
increased levels can lead to elevated inflammatory cytokine production17 and therefore, perhaps, a more catabolic
rather than anabolic effect. (4) Only a single dose of PRP
was used (ie, no repeated PRP injections), although no
research to date has shown definitive superiority with multiple injections over single injection protocols. (5) The
potential benefits of PRP for acute muscle healing may
be limited; it may be that chronic injuries/lesions respond
better than acute ones. (6) We did not quantify rat activity
after injury, which may present a confounding factor.
(7) Finally, the variability noted in the histological and
immunohistochemical analyses may be caused by slight
changes in the plane of sectioning of tissue samples.
In summary, PRP is being used to treat numerous soft
tissue injuries (including muscle contusions), although
clinical data are limited. In this rat contusion model, a local
injection of PRP into the injured gastrocnemius muscle
resulted in no significant differences in functional outcome
at various postinjury time points, indicating no likely benefit to healing. Additionally, there was no significant difference between immediate or delayed administration of PRP.
Further translational and clinical investigations need to be
performed before PRP can be recommended for the treatment of muscle contusion injuries.
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